** Shares of gene therapy maker bluebird bio BLUE.O fall 38.6% to $4.32 premarket
** Co says it would be taken private by Carlyle CG.O and SK Capital Partners
** BLUE stockholders will receive $3/shr in cash, implying an equity value of around $29.2 mln
** The offer is at an over 57% discount from the stock's last close of $7.04
** Investment firms have also offered additional $6.84/shr, contingent upon achieving certain sales milestones, which represents a payment of about $66.5 mln
** BLUE fell 69.8% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。